Immunofocus Therapeutics Named to CB Insights' 'Future Unicorn 100' List Amid IPO Filing

On December 14, 2023, the 2023 "Entrepreneur 100 Future Unicorns" list was officially released. Beijing Yimiaoshenzhou Medical Techology Co., Ltd. ("Yimiaoshenzhou") stood out among more than 300 outstanding participating companies in China with its excellent performance in technological innovation, investment value, growth speed, and development prospects, successfully making the list! This is the third time this year that the company has been awarded a "unicorn"-type honorary title by the industry, following its previous recognitions as a "Technological Innovation Near-Unicorn" and a "Potential Unicorn in China."

Unicorn companies represent the leaders of their industries, incubating new technologies, applications, and trends, and are pioneers in technological innovation. Since 2009, "Startup Bang 100" has been published consecutively for 14 years, using a professional perspective to uncover emerging commercial forces represented by potential unicorns, and discovering the driving forces behind the continuous incubation, cultivation, and rapid growth of Chinese unicorns and potential unicorns. In 2023, "Startup Bang 100" spent four months organizing and verifying data, conducting research analysis, and carrying out investigative interviews on more than 300 applicant companies, ultimately selecting 100 future unicorn enterprises.

Since its establishment in 2015, Beijing Yimiaoshenzhou Medical Technology Co., Ltd. has been committed to applying innovative gene and cell drug technologies to the treatment of major diseases such as cancer and autoimmune disorders. It has successively gained favor from multiple government-backed state-owned entities and top industry investment funds, completing nine rounds of strategic financing. The company has successfully built a one-stop, self-developed gene and cell drug research and industrialization platform, mastering key core technologies from research to production. Its product pipeline covers hematological malignancies such as lymphoma, leukemia, and myeloma, as well as solid tumors like liver cancer, colorectal cancer, gastric cancer, and pancreatic cancer. It has obtained four clinical trial approvals for two CAR-T cell category 1 new drugs, all of which have entered the registration clinical research phase. The company was also granted Beijing's first-ever Drug Manufacturing License for gene and cell therapy products. It won the highest award, the Excellence Prize, at the National Disruptive Technology Innovation Competition finals and has undertaken key national-level R&D projects including the Ministry of Science and Technology’s Key Research Plan, the Cell Therapy "Challenge Leader" technology breakthrough project under the National Innovation Center, and Beijing’s Major Science and Technology Special Projects.

As the year draws to a close, Beijing Yimiaoshenzhou Medical Techology Co., Ltd. has been listed on the "CYZONE 100 Future Unicorns" list. This not only affirms and recognizes the company's achievements in the field of technological innovation over the past year but also reflects expectations and encouragement for its future development! Moving forward, the company will focus on independent innovation and research, further intensify R&D efforts, and accelerate the pace of development. The goal is to bring its self-developed CAR-T drugs to market sooner—with lower costs, better efficacy, and improved safety—benefiting China’s vast population of cancer patients and contributing to the growth of China’s cell therapy industry and health care sector!